Interview with Esther Lim, Managing Partner, Finnegan
Finnegan is a leader and expert on the topic of intellectual property and it entered Asia in the late 1980s with an office in Tokyo yet China only very recently.…
Address: Mirae Asset Tower 28/F, Unit A-B No. 166 Lujiazui Ring Road, Pudong Shanghai, China 200120,China
Tel: 86 21 6194 2000
Web: http://www.finnegan.com/en-US/locations/region.aspx?region=5
Finnegan has more than 40 years of experience in successfully navigating U.S. IP law. Finnegan works with clients of all sizes, from virtually every industry and technology to identify, protect, advocate, and leverage their most valuable IP assets. Finnegan guides U.S. organizations as well as multinational entities that wish to conduct business in the U.S. Foreign innovators entering the U.S. market are often surprised at the intricacies of the intellectual property legal system. Patent law is becoming increasingly complex, with regulatory and legislative changes having a dramatic impact on companies’ intellectual property and business strategies. Finnegan views this complexity as an opportunity to think creatively. Finnegan’s full range of IP experience—from idea protection and management to litigation and appeals—gives the company the perspective to anticipate potential issues and devise creative solutions.
Asia boasts some of the world’s most sophisticated markets and fastest growing economies. Innovative corporations and organizations across Asia turn to Finnegan to identify, protect, advocate, and leverage their most valuable IP assets. To meet the needs of Finnegan’s Asian clients conducting business in their headquarter countries or in the United States, Finnegan has established offices in Shanghai, Taipei, and Tokyo. The firm also has strong ties to the IP legal communities in Korea and India, and our attorneys regularly travel to these countries to speak at conferences and meet with clients.
Finnegan’s licensed Foreign Representative Office in China is located in the Pudong area of Shanghai, and Finnegan’s attorneys are able to serve clients anywhere in the greater China region. As Chinese companies continue to expand their markets, Finnegan is on the ground to assist them with their U.S. IP strategies and needs.
Finnegan is proud to have been active and involved in the Chinese community for many years. We have over 30 professionals who speak Chinese, many with degrees from Chinese universities. Our local outreach efforts have included seminars, educational programs, and roundtable discussions for both business groups and universities. We are particularly active in U.S. IP licensing matters in China.
Intellectual Property Law
Finnegan is a leader and expert on the topic of intellectual property and it entered Asia in the late 1980s with an office in Tokyo yet China only very recently.…
Although MicroConstants traces its history back to 1998 in San Diego, you co-founded the China operations in 2007. What’s the story behind how that came about? It all began when…
Celgene is a relative newcomer to China. What’s the story behind how the company entered the market, and how did you yourself come to manage the local operations? I officially…
We last met with you as the head of Zuellig in 2009. Obviously, a lot has changed since then; from both a sector and corporate point of view, what have…
Among Big Pharma, Sanofi has a track record of placing a lot of faith in emerging markets – with local production, a large product portfolio, and decades of experience. As…
One of the earliest innovative biotech companies in China, Zensun has developed what its founder Dr. Zhou Mingdong calls a rare made-in-China first-in-class therapeutic candidate, Neucardin®, which has been shown…
From out meeting with BPBC in 2009, we know that your slogan is to “grow up with industry.” How have you grown up since then? Firstly, I’d like to reiterate…
Chen Qiyu, chairman of Fosun Pharma, discusses how the company is helping China achieve its ‘Healthy China 2020’ goals as well as its unique business model and company culture. Fosun…
This is our first meeting in Shanghai after being based in Beijing for two months – what if any are the differences between the two cities? At the top level,…
Hu Jintao recently announced his ambitions for China to be “an innovative country” by 2020? Could you speak to the likelihood of achieving this in terms of biotechnology as you…
You spent two decades in the US as an academic, executive, and entrepreneur, and then left to return to China and found AbMax. What’s the story behind how you came…
It seems like there’s a lot to be happy about here: Pfizer is ranked number 1 multinational R&D-based biopharmaceutical company in China, where you also have two world-class R&D centers…
The Chamber recently released this year’s European Business in China Business Confidence Survey – what were some of its key takeaways? There are four main points to the Survey. The…
See our Cookie Privacy Policy Here
